期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

降血脂药物临床合理用药研究进展 被引量：23

Clinical rational use of lipid-lowering drugs:research advances
暂未订购
导出
摘要 脂质异常是导致动脉粥样硬化的危险因素之一,对其进行调节和治疗是心血管疾病初级预防和二级预防的基础。除通过饮食调节以外,目前临床常用的治疗策略是服用降血脂药物,如他汀类、贝特类、胆固醇吸收抑制剂、烟酸、胆酸螯合剂和Ω-3脂肪酸等。这些药物作用机制不同但通常互相补充,通过合理搭配使用,可使脂质代谢异常得到纠正。本文对现有调脂药物的调脂效果和临床合理用药的研究进展进行综述。 Dyslipidemia is recognized as a risk factor for cardiovascular diseases. Adjustment and treatment of dyslipidemia is the foundation for both primary and secondary prevention of cardiovascular diseases. Besides being put on a diet, patients should take some medicines, such as statins, fibrates, bile acid sequestrants, niacin, omega-3 and so on that impact on lipid metabolism through a variety of mechanisms. This review provides an overview on how to use lipid-lowering drugs rationally when attempting to normalize serum lipid profiles and reduce risks for cardiovascular diseases and occurring of adverse drug reactions.
作者 衣淑华 衣淑珍
机构地区 山东省栖霞市人民医院心内科 海军总医院药剂科
出处 《国际药学研究杂志》 CAS 2012年第3期210-214,共5页 Journal of International Pharmaceutical Research
关键词 血脂异常 降血脂药 合理用药 药物不良反应 dyslipidemia antilipemic agents drug rational use adverse drug reaction
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献25

  • 1Fruchart JC. Peroxisome proliferator-activated receptor-alpha ac- tivation and high-density lipoprotein metabolism [ J ]. Am J Car- diol, 2001, 88(12A) :24-29.
  • 2Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabe- tes with intensive-dose compared with moderate-dose statin thera- py: a meta-analysis[ J]. JAMA, 2011, 305(24):2556-2564.
  • 3Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins [ J ]. Lancet, 2005, 366(9493) :1267-1278.
  • 4Kearney PM, BlackweU L, Collins R, et al. Efficacy of choles- terol-lowering therapy in 18 686 people with diabetes in 14 ran- domised trims of statins : a meta-analysis [ J ]. Lancet, 2008, 371 (9607) :117-125.
  • 5Toth PP, Davidson MH. High-dose statin therapy: benefits and safety in aggressive lipid lowering[ J 1. J Faro Pract, 2008, 57 (5 Suppl) : S29-S36.
  • 6Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study : a post-hoc analysis [ J ]. Lancet, 2010, 376 ( 9756 ) : 1916-1922.
  • 7USA FDA. FDA expand advice on statin risks[ EB/OL] (2011- 04-11 ) [ 2012-03-04 ]. http ://www. fda. gov/Drugs/DrugSafety/ ucm293101.
  • 8Sattar N, Preiss D, Murray HM, et al. Statins and risk of inci- dent diabetes: a collaborative meta-analysis of randomised statin trials[J]. Lancet, 2010, 375(9716) :735-742.
  • 9Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis [ J ]. Dia- betes Care, 2009, 32(10) : 1924-1929.
  • 10Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative [ J]. Arch Intern Med, 2012, 172(2) : 144-152.

二级参考文献19

  • 1吕琳,罗静,鹿克风.氟伐他汀对实验性动脉粥样硬化家兔血管壁NF-κB表达的影响[J].心肺血管病杂志,2006,25(1):43-45. 被引量：9
  • 2Klein JH,Hegele RA,Hackam DG,et al.Lipoprotein(a)is associated differentially with carotid stenasis,occlusion,and total plaque area.Arterioscler Thromb Vase Biol,2008,28:1851-1856.
  • 3Bennet A,Di Angelantonio E,Erqou S,et al.Lipoprotein(a) levels and risk of future coronary heart difease:large-scale prospective data.Arch Intern Med,2008,168:598-608.
  • 4Clarke R,Peden JF,Hopewell JC,et al.Genetic variants associated with Lp(a) lipoprotein level and coronary disease.N Engl J Med,2009,361:2518-2528.
  • 5Erqou S,Kaptoge S,Perry PL,et al.Lipoprotein(a)concentration and the risk of coronary heart disease,stroke,and nonvaseular mortality.JAMA,2009,302:412-423.
  • 6Biche DM,East HE,Priest HM.Practical management of dyslipidemia with elevated lipoprotein(a).J Am Pharm Assoc (2003),2008,48:803-807.
  • 7Sharma M,Sharma DR,singh V,et al.Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients:a multicentric study.Vasc Health Risk Manag,2006,2:87-93.
  • 8Scanu AM,Bamba R.Niacin and lipopmtein(a):facts,uncertainties,and clinical considerations.Am J Cardiol,2008,101:44B-47B.
  • 9Sposito AC,Mansur AP,Maranhao RC,et al.Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein(a) in type IIb dyslipidemic subjects.Braz J Med Biol Res,2001,34:177-182.
  • 10Bergmark C,Dewan A,Orsoni A,et al.A novel function of lipoprotein[a] as a preferential carrier of oxidized phospholipids in human plasma.J Lipid Res,2008,49:2230-2239.

共引文献13

同被引文献147

引证文献23

二级引证文献101

国际药学研究杂志
2012年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部